Take a look at our previous reports:

GLPG5101: CD19 CAR-T to expand to eight aggressive B-cell malignancies, broadening patient reach and impact

GLPG5101 is a second generation anti-CD19/4-1BB CAR-T product candidate, administered as a single fixed intravenous dose. The safety, efficacy and feasibility of decentralized manufactured GLPG5101 are currently being evaluated in the ATALANTA-1 Phase 1/2 study in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

The primary objective of the Phase 1 part of the study is to evaluate safety and to determine the recommended dose for the Phase 2 part of the study. Secondary objectives include assessment of efficacy and feasibility of decentralized manufacturing of GLPG5101.

The dose levels that were evaluated in Phase 1 are 50x106 (DL1), 110x106 (DL2) and 250x106 (DL3) CAR+ viable T-cells.

The primary objective of the Phase 2 part of the study is to evaluate the Objective Response Rate (ORR) while the secondary objectives include Complete Response Rate (CRR), duration of response, progression free survival, overall survival, safety, pharmacokinetic profile, and the feasibility of decentralized manufacturing. Each enrolled patient will be followed for 24 months.

ATALANTA-1 phase 1/2 study design and objectives

ATALANTA-1 phase 1/2 study design and objectives (graphic)
aPatients with no prior therapies and IPI 3–5, or double/triple-hit lymphoma on interim PET scan. bScreening could take place up to a maximum of 28 days prior to leukapheresis. cConditioning chemotherapy: fludarabine IV (30 mg/m2/day); cyclophosphamide IV (300 mg/m2/day). BL, Burkitt lymphoma; Cy, cyclophosphamide; FL, follicular lymphoma; Flu, fludarabine; (HR) DLBCL, (high-risk) diffuse large B-cell lymphoma; IPI, international prognostic index; IV, intravenous; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; ORR, objective response rate; PCNSL, primary central nervous system lymphoma; PET, positron emission tomography; RP2D, recommended Phase 2 dose.

Demographics and baseline characteristics of ATALANTA-1:
heavily pre-treated NHL patient population

Demographics and baseline characteristics of ATALANTA-1: heavily pre-treated NHL patient population

 

Phase 1

Phase 2

Characteristic

DL1
n = 7

DL2
n = 11

DL3
n = 2

All patients
N = 20

All patients
N = 25

Age, median (range), years

63.0 (50–77)

67.0 (25–78)

67.5 (63–72)

66.5 (25–78)

67.0 (40–81)

Male sex, n (%)

7 (100)

5 (46)

1 (50)

13 (65)

16 (64)

Race: white, n/n available (%)

7/7 (100)

10/10 (100)

1/1 (100)

18/18 (100)

25/25 (100)

NHL subtype, n (%)

 

 

 

 

 

DLBCL

4 (57)

7 (64)

2 (100)

13 (65)

0

MCL

2 (29)

1 (9)

0

3 (15)

5 (20)

FL

1 (14)

2 (18)

0

3 (15)

16 (64)

MZL

0

1 (9)

0

1 (5)

4 (16)

IPI/MIPI/FLIPI score at screening, high risk, n (%)

3 (43)

4 (40)

1 (50)

8 (42)

14 (56)

ECOG PS: 0/1/2 n (%)

4(57) /
3(43) /
0

3(27) /
7(64) /
1(9)

0 /
2(100) /
0

7(35) /
12(60) /
1(5)

13(52) /
7(28) /
5(20)

All prior therapies, median (range)

3 (2–7)

2 (1–7)

1.5 (1–2)

2.5 (1–7)

3 (2–11)

Prior systemic therapies, median (range)

3 (2–6)

2 (1–6)

1.5 (1–2)

2 (1–6)

3 (2–6)

Ann Arbor disease stage: II/III–IV, n (%)

0 /
7(100)

1(9) /
10(91)

1(50) /
1(50)

2(10) /
18(90)

5(20) /
20(80)

DL1 = 50 × 106 CAR+ T cells; DL2 = 110 × 106 CAR+ T cells; DL3 = 250 × 106 CAR+ T cells. Data cutoff: April 25, 2024. CAR, chimeric antigen receptor; DL, dose level; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; (M, FL)IPI, (MCL, FL) international prognostic index; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma

In December 2024, we presented new data4 from the ongoing ATALANTA-1 Phase 1/2 study at the 2024 Annual Meeting of the American Society of Hematology (ASH) Meeting, which included updated data on patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) / follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

As of the data cut-off on April 25, 2024, 49 patients had received cell therapy infusion, and safety and efficacy results were available for 45 patients and 42 patients, respectively. The results are summarized below:

  • High objective response rates (ORR) and complete response rates (CRR) were observed in the pooled Phase 1 and Phase 2 efficacy analysis set, split by indication:
    • In MCL, all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%).
    • In MZL/FL, objective and complete responses were observed in 20 of 21 efficacy-evaluable patients (ORR and CRR 95%).
    • In DLBCL, 9 of 13 efficacy-evaluable patients responded to treatment (ORR 69%), with 7 patients achieving a complete response (CRR 54%). Of the 7 patients with DLBCL who received the higher dose, 6 responded to treatment (ORR 86%) while 5 achieved a complete response (CRR 71%).
  • Of the 15 minimal residual disease (MRD)-evaluable patients with a complete response, 12 patients (80%) achieved MRD negativity and remained in complete response at data cut-off.
  • The median study follow-up was 3.3 months for FL and DLBCL with a range of 0.9-21.2 months, and 4.4 months for MCL with a range of 1-24.4 months.
  • GLPG5101 showed an encouraging safety profile, with the majority of Grade ≥ 3 treatment emergent adverse events being hematological. One case of CRS Grade 3 was observed in Phase 1 and one case of ICANS Grade 3 was observed in Phase 2.
  • 96% of patients (47 of 49) received an infusion with fresh, fit, stem-like early memory (naïve/stem cell memory and central memory) CD19 CAR T-cell therapy, with 91.5% (43 of 47) achieving a vein-to-vein time of seven days, thereby avoiding cryopreservation, and eliminating the need for bridging therapy. 
  • Strong and consistent in vivo CAR-T expansion levels and products consisting of stem-like, early memory phenotype T-cells were observed in all doses tested. This early phenotype reflects the differentiation status of the cells, which is associated with enhanced functionality and persistence of CAR-T cells, which could potentially be an early predictor of durable responses after infusion.
  • Beyond MCL, MZL/FL and DLBCL, the ATALANTA-1 study also includes high-risk first line DLBCL, Burkitt lymphoma (BL), and primary CNS lymphoma (PCNSL). Patient recruitment is ongoing in Europe. With the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance secured, leading cancer centers in Boston have been activated, and patient screening has begun. Boston-based Landmark Bio is operational and serves as the decentralized manufacturing unit (DMU) for ATALANTA-1. 
  • Building on these encouraging data and in line with its goal to streamline the business, we are focusing our resources on accelerating GLPG5101 as our flagship CD19 CAR-T program, and pending the advancement of GLPG5101 in additional indications, are deprioritizing activities for GLPG5201, our second CD19 CAR-T candidate. With the addition of double-refractory chronic lymphocytic leukemia (CLL) and Richter transformation (RT) of CLL, both indications with significant unmet needs, GLPG5101 would be developed across eight aggressive B-cell malignancies, further unlocking its broad potential to address significant unmet medical needs.
  • We aim to present additional new data at a medical meeting in 2025.

Encouraging efficacy data:
ATALANTA-1 preliminary pooled Phase 1/2 results in heavily pretreated patient population

High OR and CR rates were observed (best response at any time after infusion)a

ATALANTA-1 preliminary pooled Phase 1/2 results in heavily pretreated patient population (graphic)
aTwo patients who received cryopreserved product were not included in the efficacy analyses; both patients were in CR at data cutoff. bThree patients with FL were not included in the Phase 2 response outputs as the first response assessment data were not available at data cutoff. Data cutoff: 25 April 2024. CR, complete response; CRR, complete response rate; DL, dose level; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; OR, objective response; ORR, objective response rate; PR, partial response

Encouraging safety profile:
ATALANTA-1 preliminary results in heavily pretreated patient population

ATALANTA-1 preliminary results

 

Phase 1

Phase 2

TEAEs up to 14 weeks after infusion
(end of treatment)

DL1
n = 7

DL2
n = 11

DL3
n = 2

All patients
N = 20

All patients
N = 25

Any TEAE, n (%)

7 (100)

11 (100)

2 (100)

20 (100)

24 (96)

Any GLPG5101-related TEAE, n (%)

7 (100)

11 (100)

2 (100)

20 (100)

21 (84)

Serious TEAE, n (%)

2 (29)

3 (27)

0

5 (25)

2 (8)

TEAE leading to death, n (%)

0

1 (9)

0

1 (5)

0

Any Grade ≥ 3 TEAE, n (%)

7 (100)

11 (100)

2 (100)

20 (100)

18 (72)

Hematologic Grade ≥ 3 TEAEs, n (%)

Neutropeniaa

6 (86)

11 (100)

2 (100)

19 (95)

15 (60)

Lymphopeniab

4 (57)

2 (18)

0

6 (30)

5 (20)

Anemiac

2 (29)

4 (36)

0

6 (30)

2 (8)

Thrombocytopeniad

3 (43)

1 (9)

0

4 (20)

4 (16)

Leukopeniae

2 (29)

5 (45)

1 (50)

8 (40)

7 (28)

Other Grade ≥ 3 TEAEs in ≥ 2 patients,f n (%)

Pyrexia

1 (14)

1 (9)

 

2 (10)

1 (4)

Pleural effusion

1 (14)

1 (9)

 

2 (10)

0

DL1 = 50 × 106 CAR+ T cells; DL2 = 110 × 106 CAR+ T cells; DL3 = 250 × 106 CAR+ T cells.

a

Includes neutropenia/neutrophil count decreased.

b

Includes lymphopenia/lymphocyte count decreased.

c

Includes anemia/hemoglobin decreased.

d

Includes thrombocytopenia/platelet count decreased.

e

Includes leukopenia/white blood cell count decreased.

f

In either the Phase 1 or Phase 2 total population.

Data cutoff: April 25, 2024

CAR, chimeric antigen receptor; DL, dose level; TEAE, treatment-emergent adverse event

GLPG5101 product characteristics

  • The CD4:CD8 ratio of CAR+ T cells increased in the final product as compared to the ratio of CD4:CD8 T cells in the starting material (median [Q1, Q3] increase of 0.8 [0.05, 2.02]) 
  • The proportion of early phenotype CD4+ and CD8+ CAR T cells increased significantly in the final product, compared to the early phenotype CD4+ and CD8+ T cells in the starting material
GLPG5101 product characteristics (graphic)
Exploratory flow cytometry analysis of T-cell subsets in the apheresis starting material and final product. Nonparametric paired-samples Wilcoxon tests were used to assess the statistical significance of the differences in early memory phenotype T-cell subsets (TN/TSCM and TCM) in the final product compared with the starting material. Early phenotype CD4+ and CD8+ (CAR) T cells: naïve/stem cell memory T cells (CD45ROCD197+ TN/SCM ); central memory T cells (CD45RO+CD197+ TCM). Percentage of early phenotype T cells (sum of CD45ROCD197+ TN/SCM and CD45RO+CD197+ TCM ) of CD4+ or CD8+ (gated on CAR+ T cells for final product) for paired patient samples (N = 40). Data cutoff: 25 April 2024. ***P < 0.001; med, median; Q, quartile; TCM, central memory T cells; TN/SCM, naïve/stem cell memory T cells

The fitness of the final product was evaluated by measuring the level of CAR T-cell expansion. We observed robust CAR T-cell expansion in treated patients across all dose levels. At the cut-off date of April 24, 2024, 15 out of 18 evaluable patients (83%) had detectable CAR T-cells at 6 months post-infusion: 75% in Phase 1 and 100% in Phase 2. Persisting CAR T-cells could be detected up to 21 months post-infusion. These findings support persistence of GLPG5101, which could be an early predictor of durable responses.

Cellular expansion and durable persistence of GLPG5101
Quantification of GLPG5101 up to Day 28 post-infusion (Phase 1)a

Cellular expansion and durable persistence of GLPG5101 (graphic)
Cellular expansion and durable persistence of GLPG5101

Phase 1

DL1
n = 7

DL2
n = 11

DL3
n = 2

All patients
N = 20

Median AUCd0–28,
copies/μg DNA × days
(min, max)

3.5 × 106
(6.6 × 105,
1.7 × 107)

2.9 × 106
(5.0 × 105,
7.9 × 106)

3.4 × 106
(1.2 × 106,
5.5 × 106)

3.2 × 106
(5.0 × 105,
1.7 × 107)

Persistence after Day 28 post-infusiona,b
  • 15/18 (83%) patients had detectable GLPG5101 in peripheral blood at Month 6 post-infusion:
    • 9/12 (75%) in Phase 1
    • 6/6 (100%) in Phase 2
  • Persisting CAR T cells could be detected up to 21 months post-infusion

Quantification of GLPG5101 in peripheral blood using aqPCR (LOQ: 1000 vector copies) and bdPCR (LOQ: 50 vector copies/μg DNA).  AUCd0–28, area under the curve from Day 0 to 28; D, Day; (d/q)PCR, (digital/quantitative) polymerase chain reaction; DL, dose level; LOQ, limit of quantification; S, screening

These initial results reinforce the potential of Galapagos’ innovative, decentralized cell therapy manufacturing platform to deliver fresh, stem-like, early memory CD19 CAR T-cell therapy, with a median vein-to-vein time of seven days.

Building on these encouraging data and in line with our goal to streamline the business as announced on January 8, 2025 and February 12, 2025, we are focusing our resources on accelerating GLPG5101 as our flagship CD19 CAR-T program, and pending the advancement of GLPG5101 in additional indications, are deprioritizing activities for GLPG5201, our second CD19 CAR-T candidate. With the addition of double-refractory chronic lymphocytic leukemia (CLL) and Richter transformation (RT) of CLL, both indications with significant unmet needs, GLPG5101 would be developed across eight aggressive B-cell malignancies, further unlocking its broad potential to address significant unmet medical needs.

ATALANTA-1
ATALANTA-1 Phase 1/2 study with decentralized manufactured CD19 CAR-T candidate, GLPG5101, in different aggressive B-cell malignancies
Burkitt lymphoma (BL)
BL is a rare, aggressive form of NHL that arises from B-lymphocytes, a type of white blood cells that produce antibodies. BL is the most common form of NHL in children, but it can also develop in adults. BL is more common in males than in females
CAR-T
Chimeric antigen receptor T cells (also known as CAR-T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy
CD19
CD19 is a protein found on the surface of B-cells, a type of white blood cell. Since CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell, notably B-cell lymphomas
Cell therapy
Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells)
Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia is the most common leukemia in adults. It is a type of cancer that starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells originate in the bone marrow and migrate to the bloodstream
Complete Response Rate (CRR)
Term used for the absence of all detectable cancer after the treatment is completed
Cryopreservation
Process where biological material - cells, tissues, or organs - are frozen to preserve the material for an extended period of time
Cytokine release syndrome (CRS)
Condition that develops when your immune system responds too aggressively to infection or after certain types of immunotherapy, such as CAR-T-cell therapy
Efficacy
Effectiveness for intended use
FDA
The U.S. Food and Drug Administration is an agency responsible for protecting and promoting public health and in charge of American market approval of new medications
GLPG5101
A second generation anti-CD19/4-1BB CAR-T product candidate currently in Phase 1/2 study in multiple aggressive B-cell malignancies
GLPG5201
A second generation anti-CD19/4-1BB CAR-T product candidate in Phase 1/2 study in R/R CLL/SLL and RT
Investigational New Drug (IND) Application
United States Federal law requires a pharmaceutical company to obtain an exemption to ship an experimental drug across state lines, usually to clinical investigators, before a marketing application for the drug has been approved. The IND is the means by which the sponsor obtains this exemption, allowing them to perform clinical studies
Non-Hodgkin's lymphoma (NHL)
Non-Hodgkin lymphoma is a type of cancer that begins in the lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin lymphoma, white blood cells called lymphocytes grow abnormally and form tumors throughout the body
Objective Response Rate (ORR)
The response rate is the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment. When used as a clinical endpoint for trials of cancer treatments, this is often called the objective response rate
Phase 1
First stage of clinical testing of an investigational drug designed to assess the safety and tolerability, pharmacokinetics of a drug, usually performed in a small number of healthy human volunteers
Phase 2
Second stage of clinical testing, usually performed in no more than several hundred patients, in order to determine efficacy, tolerability and the dose to use
Product candidate
Substance that has satisfied the requirements of early preclinical testing and has been selected for development, starting with formal preclinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans
Refractory
"Refractory" refers to a patient with cancer that is/has become resistant to, or does not respond to, treatment
Relapsed
"Relapsed" refers to a patient with cancer that develops cancer again after a period of improvement
Richter transformation
Richter transformation (RT) is an uncommon clinicopathological condition observed in patients with CLL. It is characterized by the sudden transformation of the CLL into a significantly more aggressive form of large cell lymphoma, and occurs in approximately 2-10% of all CLL patients

4 4Data presented at ASH 2024 (Kersten MJ, et al). Oral ASH presentation #93, 7 Dec 2024. Cut-off date: April 25, 2024